Thrombocytosis and outcomes: logistic regression analyses
| Predictor | OR | 95% CI | p Value |
|---|---|---|---|
| Total mortality | |||
| Platelet count >400×109 cells/mm3 | 1.53 | 1.03 to 2.29 | 0.030 |
| Age | 1.02 | 1.01 to 1.04 | 0.0007 |
| Congestive cardiac failure | 1.52 | 1.11 to 2.10 | 0.009 |
| Neoplastic disease | 2.65 | 1.78 to 3.96 | <0.0001 |
| MRC dyspnoea score | 1.81 | 1.54 to 2.13 | <0.0001 |
| Long term oxygen therapy | 1.66 | 1.09 to 2.55 | 0.021 |
| Acidosis during exacerbation | 2.15 | 1.53 to 3.03 | <0.0001 |
| Antiplatelet therapy | 0.60 | 0.43 to 0.83 | 0.002 |
| Hosner–Lemeshow goodness of fit test p=0.676 | |||
| Inhospital mortality | |||
| Platelet count >400×109 cells/mm3 | 2.37 | 1.29 to 4.34 | 0.005 |
| Age | 1.03 | 1.01 to 1.06 | 0.030 |
| Congestive cardiac failure | 1.75 | 1.06 to 2.91 | 0.034 |
| Neoplastic disease | 1.79 | 1.00 to 3.24 | 0.048 |
| Acidosis | 5.24 | 3.16 to 8.68 | <0.0001 |
| BAP-65 Hosner–Lemeshow goodness of fit test, p=0.960 | 1.82 | 1.37 to 2.43 | <0.0001 |
| Mortality after discharge | |||
| Platelet count >400×109 cells/mm3 | 1.30 | 0.82 to 2.06 | 0.261 |
| Age | 1.02 | 1.00 to 1.03 | 0.024 |
| Congestive cardiac failure | 1.60 | 1.06 to 2.39 | 0.022 |
| Neoplastic disease | 2.48 | 1.60 to 3.82 | <0.0001 |
| MRC dyspnoea score | 2.06 | 1.73 to 2.46 | <0.0001 |
| Long term oxygen therapy | 1.64 | 1.04 to 2.60 | 0.030 |
| Antiplatelet therapy | 0.59 | 0.43 to 0.81 | 0.001 |
| Resident in long term care facility | 2.21 | 1.17 to 4.19 | 0.015 |
| Hosner–Lemeshow goodness of fit test p=0.502 | |||
Logistic regression models investigating the impact of thrombocytosis on outcomes after exacerbation of COPD.
MRC, Medical Research Council.